CN107927498A - A kind of beverage composition for treating dental erosion and its application for suppressing lithangiuria and forming and promote dissolve stone - Google Patents
A kind of beverage composition for treating dental erosion and its application for suppressing lithangiuria and forming and promote dissolve stone Download PDFInfo
- Publication number
- CN107927498A CN107927498A CN201711210091.1A CN201711210091A CN107927498A CN 107927498 A CN107927498 A CN 107927498A CN 201711210091 A CN201711210091 A CN 201711210091A CN 107927498 A CN107927498 A CN 107927498A
- Authority
- CN
- China
- Prior art keywords
- gamboge
- berry extract
- lithangiuria
- beverage
- stone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004575 stone Substances 0.000 title claims abstract description 32
- 235000013361 beverage Nutrition 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title abstract description 6
- 230000003628 erosive effect Effects 0.000 title abstract description 4
- 229940117709 gamboge Drugs 0.000 claims abstract description 53
- 241000598860 Garcinia hanburyi Species 0.000 claims abstract description 47
- 235000021028 berry Nutrition 0.000 claims abstract description 44
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 6
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 230000001629 suppression Effects 0.000 claims abstract description 5
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 235000019441 ethanol Nutrition 0.000 claims description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 241000598812 Garcinia tinctoria Species 0.000 claims description 6
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 6
- 229940075582 sorbic acid Drugs 0.000 claims description 6
- 235000010199 sorbic acid Nutrition 0.000 claims description 6
- 239000004334 sorbic acid Substances 0.000 claims description 6
- 238000010898 silica gel chromatography Methods 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 4
- 241000593508 Garcinia Species 0.000 claims description 3
- 235000000885 Garcinia xanthochymus Nutrition 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 235000021552 granulated sugar Nutrition 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 3
- 229920001277 pectin Polymers 0.000 claims description 3
- 235000010987 pectin Nutrition 0.000 claims description 3
- 239000001814 pectin Substances 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 229940013618 stevioside Drugs 0.000 claims description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 3
- 235000019202 steviosides Nutrition 0.000 claims description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 1
- 238000004440 column chromatography Methods 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 abstract description 15
- 210000002700 urine Anatomy 0.000 abstract description 15
- 239000013078 crystal Substances 0.000 abstract description 13
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract description 8
- 229910001424 calcium ion Inorganic materials 0.000 abstract description 8
- 210000005239 tubule Anatomy 0.000 abstract description 8
- 235000006408 oxalic acid Nutrition 0.000 abstract description 7
- 230000008021 deposition Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 241000700159 Rattus Species 0.000 description 15
- 210000003734 kidney Anatomy 0.000 description 9
- 238000002425 crystallisation Methods 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000008399 tap water Substances 0.000 description 5
- 235000020679 tap water Nutrition 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 208000031816 Pathologic Dilatation Diseases 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QLOKJRIVRGCVIM-UHFFFAOYSA-N 1-[(4-methylsulfanylphenyl)methyl]piperazine Chemical compound C1=CC(SC)=CC=C1CN1CCNCC1 QLOKJRIVRGCVIM-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010007027 Calculus urinary Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000000913 Kidney Calculi Diseases 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- 208000009911 Urinary Calculi Diseases 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001577 simple distillation Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- ZPLCXHWYPWVJDL-UHFFFAOYSA-N 4-[(4-hydroxyphenyl)methyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(O)=CC=C1CC1NC(=O)OC1 ZPLCXHWYPWVJDL-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical class [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- IPCAPQRVQMIMAN-UHFFFAOYSA-L zirconyl chloride Chemical compound Cl[Zr](Cl)=O IPCAPQRVQMIMAN-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a kind of beverage composition for treating dental erosion and its application for suppressing lithangiuria and forming and promote dissolve stone.The present invention relates to a kind of new application of gamboge berry extract, i.e. application of the gamboge berry extract in the formation of suppression lithangiuria is prepared, promote the food or medicine of dissolve stone.The present invention also provides a kind of beverage for suppressing lithangiuria and being formed and promoting dissolve stone.Its advantage is shown：First passage zoopery of the present invention finds that gamboge berry extract can inhibit lithangiuria and be formed, promote dissolve stone.Relative to stone group is lured, gamboge berry extract intervention group rat 24h urine concentration of oxalic acid, calcium ion concentration significantly reduce；Visible point-like calcium oxalate crystal in gamboge berry extract intervention group renal tubule, rare slabbing, calcium oxalate crystal deposition and tube chamber expand situation and substantially relatively lure stone group to improve.
Description
Technical field
The present invention relates to food, field of pharmaceutical technology, is that a kind of lithangiuria that suppresses forms and promote dissolve stone specifically
Beverage composition for treating dental erosion and its application.
Background technology
Kidney stone is a kind of as caused by environment dietary factor and inherent cause common, multiple, body mineralising answer
Miscellaneous disease, incidence are up to 10-20%, and the life, work and health to patient make a big impact.At present to kidney stone disease
Treatment mainly have four class treatment methods：General treatment (great quantity of water drinking, intramuscular injection lead directly to medicine, medicine row stone), external knock wave
Lithotrity, intracavity operation treatment and open operation treatment.
Calcinm oxalate calculus component is the highest type of accounting in stone in urinary system, and clinic has intervention to stone in urinary system at present
The medicine of effect mainly adjusts urine ph values, and mainly for calculus urate, because calculus urate is in pH value<Solubility when 5.5
Low, solubility lithate is dominant during pH value increase, and urine ph values calcium oxalate crystals are influenced it is little.
Chinese patent literature CN101485677A discloses application of the polysaccharides in urinary calculus is prevented.It passes through experiment
Show, suitable polysaccharides, which can reduce to drink, lures the kidney calcinm oxalate calculus of stone agent rat to be formed, its mechanism of action is probably logical
Antioxidation reaction is crossed, damage of the free radical to nephridial tissue is reduced, so as to reduce the apoptosis of renal cells.Chinese patent text
Offer CN105982930A and disclose the application that Herba Desmodii Styracifolii extract treats urinary calcinm oxalate calculus.Chinese patent literature
CN101433549A discloses a kind of calcium oxalate crystal inhibitor, is made of nanometer selenium.But have no on gamboge berry extract
The report of urinary calculus is prevented, also has no that the suppression lithangiuria of the present invention forms and promote the report of the composition of dissolve stone.
The content of the invention
The purpose of the present invention is for deficiency of the prior art, there is provided a kind of new application of gamboge berry extract.
Second object of the present invention is to provide a kind of composition for suppressing lithangiuria and being formed and promoting dissolve stone.
To achieve the above object, the present invention adopts the technical scheme that：
Application of the gamboge berry extract in the formation of suppression lithangiuria is prepared, promote the food or medicine of dissolve stone.
The food is beverage.
The lithangiuria is calcinm oxalate calculus, and it is to promote calcinm oxalate calculus dissolving to promote dissolve stone.
The gamboge berry extract is water extract or alcohol extracting thing.
The gamboge berry extract is made by the following method：
(1) dry gamboge shell is cut into pieces, the soak extraction in boiling water, extracting solution concentration is medicinal extract；
(2) ethanol is added into medicinal extract to be dissolved, filter out pectin, obtain concentrate.
The gamboge berry extract is made by the following method：
(1) by gamboge pericarp ethanol soak extraction, it is gamboge pericarp to be extracted to soak the ethanol volume used every time
8 times of quality, when immersion 48 is small every time, soak extraction 3 times, merges ethanol soaked extracting solution altogether, and the absolute ethyl alcohol that is concentrated under reduced pressure obtains
To extractum A；
(2) silica gel column chromatography separation is carried out to extractum A：Silica gel dosage is 18 times of medicinal extract, and specification is 200 mesh, and extractum A is adopted
Being eluted with silica gel column chromatography with chloroform, elute 8 column volumes, the chloroform eluent that is concentrated under reduced pressure obtains medicinal extract B,
Medicinal extract B obtains gamboge berry extract after drying.
To realize above-mentioned second purpose, the present invention adopts the technical scheme that：One kind suppresses lithangiuria and is formed and promoted
Into the beverage of dissolve stone, the gamboge berry extract of 0.1wt%~10wt% is included in the beverage.
The content of gamboge berry extract is 2wt%.
The beverage is made of following components：Gamboge berry extract 2wt%, stevioside 1wt%, sorbic acid 0.1wt%,
Water 96.9wt%.
The beverage is made of following components：Gamboge berry extract 2wt%, white granulated sugar 1wt%, sorbic acid 0.1wt%,
Water 96.9wt%.
The invention has the advantages that：
1st, first passage zoopery of the present invention finds that gamboge berry extract can inhibit lithangiuria and form and promote dissolve stone：
Relative to stone group is lured, gamboge berry extract intervention group rat 24h urine concentration of oxalic acid, calcium ion concentration significantly reduce；Garcinia Cambogia carries
Visible point-like calcium oxalate crystal in thing intervention group renal tubule, rare slabbing are taken, calcium oxalate crystal deposition and tube chamber expand situation
It is obvious relatively to lure stone group to improve.
2nd, present invention also offers berry extract containing gamboge, it can inhibit the beverage that lithangiuria forms and promotes dissolve stone.
Brief description of the drawings
Attached drawing 1 is each group rat kidney pathological section calcium oxalate crystal growth in healthy Crystallization and tubular ectasia situation.
Embodiment
Elaborate with reference to embodiment to embodiment provided by the invention.
Embodiment 1
The preparation process of gamboge berry extract：
(1) dry gamboge shell is cut into pieces, the soak extraction in boiling water, extracting solution concentration is medicinal extract；
(2) ethanol is added into medicinal extract to be dissolved, filter out pectin, obtain concentrate.
Embodiment 2
(1) by gamboge pericarp ethanol soak extraction, it is gamboge pericarp to be extracted to soak the ethanol volume used every time
8 times of quality, when immersion 48 is small every time, soak extraction 3 times, merges ethanol soaked extracting solution altogether, and the absolute ethyl alcohol that is concentrated under reduced pressure obtains
To extractum A.
(2) silica gel column chromatography separation is carried out to extractum A：Silica gel dosage is 18 times of medicinal extract, and specification is 200 mesh, and extractum A is adopted
Being eluted with silica gel column chromatography with chloroform, elute 8 column volumes, the chloroform eluent that is concentrated under reduced pressure obtains medicinal extract B,
Medicinal extract B obtains gamboge berry extract after drying.
Gamboge berry extract used in following embodiments prepares for the present embodiment preparation process.
Embodiment 3
First, zoopery is grouped：
No-special pathogen (SPF) level male SD rat 24,200~250g of weight.Normal granules feed and tap water
Feed and adapt to environment after 1 week, be randomly divided into three groups, every group 8.A groups (control group)：Normal granules feed and tap water in experiment
Feed；B groups (lure stone group)：With containing 1% ammonium chloride and 1% ethylene glycol solution 2ml/d gavages in experiment, normal granules feed and from
Water is fed；C groups (gamboge berry extract intervention group)：Drunk in experiment containing 1% ammonium chloride and 1% ethylene glycol solution 2ml/d fillings
The gamboge berry extract of stomach+2%, normal granules feed and tap water are fed.
2nd, collection of specimens：
Experiment carried out for 2 week, is putting to death rat the previous day, each male SD rat is placed in the open metabolism of cleaning grade
In cage, 24h urines are left and taken, carry out the detection of urine index of correlation.Secondary daily 3% yellow Jackets (40mg/kg) carry out abdominal cavity
After anesthesia, routine disinfection drape, takes belly midsection, successively exposed to abdominal cavity, pushes the internal organs such as the intestines and stomach in abdominal cavity open, appears
Cavity of resorption artery and vein, microinstrument separate kidney fascia to adipose capsule, appear kidney.Inferior caval vein blood sampling 5-8ml, centrifugation
Supernatant is taken after (3500r/min, 5min), treats the detection of Serum markers.After taking blood, the kidney of bilateral is removed, wipes out kidney
All remaining adipose tissue and vessel pedicle, electronic balance weighing.Kidney is cut into the two halves of equalization along coronal-plane, is positioned in 10%
Property formalin fix 24h after, row paraffin embedding.
3rd, Testing index and detection method
1.24h urines concentration of oxalic acid measures：The urine that every rat is collected, metering, enriching hydrochloric acid anti-corrosion, 4 DEG C of preservations.
It is as follows according to the red catalytic spectrophotometric urine oxalic acid of potassium chromate oxidation methyl, its method：Three 20.0ml test tubes are taken, make sample respectively
Quality control (Au), standard pipe (As) and blank tube (Ab).The mixing urine for using simple distillation water to dilute 10 times is added in sample cell
0.5ml, adds oxalic acid standard working solution 0.5ml in standard pipe, then respectively plus distilled water 1.0ml, in blank tube plus simple distillation water
1.5ml, each pipe plus bromothymol blue indicator 1 drip, and 0.25mmol/L sodium hydroxides, which are added dropwise, makes test tube liquid into blue-green, total amount
No more than 0.5ml.Saturation calcium sulfate 2.0ml and 95% ethanol is added to be mixed, capping to 20.0ml.When room temperature placement 3 is small, with
2500r/min, centrifuges 10min, and incline supernatant, is inverted on filter paper the raffinate that exhausts, then add 0.4mol/L hydrochloric acid 2.0ml to make to sink
Form sediment and dissolve, be transferred to respectively in the colorimetric cylinder of three 10ml, each red 2.0ml, 1.0mmol/L potassium chromate 4.0ml of methylate, uses water
Scale is diluted to, is shaken up, timing, when 15min, adds 1.0mmol/L zirconyl chloride solution 1.0ml, shakes up, pours into 1cm cuvettes,
Reference is made with water, JH-722 type spectrophotometers survey absorbance at 515nm.By formula (1)：C (mmol/L)=(Ab-Au)/
(Ab-As) × 0.01
The measure of 2.24h urinary calcium concentration：Measured by AU800 full automatic biochemical apparatus.
3. creatinine, urea nitrogen in blood：Creatinine, urea nitrogen are measured using bitter taste acid colorimetric method by AU800 full automatic biochemical apparatus.
4. calcium in blood, the concentration of phosphorus：AU800 biochemical instruments measure.
5. nephridial tissue row HE is dyed, the situation of the distribution of Microscopic observation renal tubule Calcium Oxalate and tubular ectasia, and
Score crystallization.
1) cut into slices, II grade of dimethylbenzene is transparent, dewaxes each 10 minutes.
2) graded ethanol aquation is cut into slices.
3) haematoxylin dyeing 5 minutes, tap water rinse 5 minutes.
4) hydrochloride alcohol color separation 5-10 seconds, tap water rinsed 5 minutes.
5) Yihong dyestuff is redyed 3-5 minutes.
6) gradient alcohol dehydration.
7) II grade of dimethylbenzene is transparent.
8) neutral gum mounting.
6. criterion and the method for pathological change degree：
After rat kidney tissue HE dyeing, in 200 times of light Microscopic observation nephridial tissue calcium oxalate crystal depositions and carry out
Classification：
0 grade：Without any crystallization bright spot.
I grade：Tiny crystallization refractive power bright spot is extensive but not in heaps.
II grade：Crystallize refractive power and become thick, in heaps, but be dispersed in and be not connected to.
III grade：Crystallization refractive power in heaps locally interconnects.
IV grade：Extensive crystallization refractive power in heaps, connection are in blocks.
4th, the statistical analysis of experimental data：
All inspection results are represented with mean ± standard deviation, using SPSS13.0 statistical softwares, multiple sample averages
Compare and use variance analysis, the difference between each group is compared with one-way analysis of variance, crystallization scoring carries out statistics with rank sum test
Analysis, it is statistically significant for difference with P ＜ 0.05.
5th, experimental result
1st, each group rat 24h urinates concentration of oxalic acid, the situation of change (see the table below) of calcium ion concentration
1 each group rat 24h of table urine concentration of oxalic acid, the situation of change of calcium ion concentration
*：Compared with normal group (A groups), P<0.05；
#：Compared with luring stone group (B groups), P<0.05；
Each group rat 24h urine Ox concentration difference has significant；There were significant differences for three groups of rat 24h urine Ca2+ concentration；
Meanwhile 24h urine Ox, Ca2+ concentration of two groups of B, C, hence it is evident that higher than A groups, difference there were significant differences (P<0.05), C groups and B groups ratio
It is decreased obviously compared with, 24h urine Ox, Ca2+ content, difference there were significant differences (P<0.05).
2nd, each group blood biochemistry of rats index (see the table below).
2 each group blood biochemistry of rats index of table
*:Compared with normal group (A groups), P<0.05
#:Compared with luring stone group (B groups), P<0.05
B, the Serum BUN concentration of two groups of C, hence it is evident that higher than A groups, there were significant differences for difference (P ﹤ 0.05)；B groups compared with C groups,
Two groups of Serum BUN concentration difference is without significant difference (P ﹥ 0.05)；B, the change of serum C r concentration of two groups of C, hence it is evident that higher than A groups, have aobvious
Write difference (P ﹤ 0.05)；For B groups compared with C groups, B groups serum (Cr) concentration is higher than C groups, and there were significant differences (P ﹤ 0.05)；Between each group
Serum (Ca2+) concentration, without significant difference (P ﹥ 0.05) between group.Serum (P) concentration between each group, without significant difference (P ﹥ between group
0.05)。
3rd, each group rat kidney pathological section calcium oxalate crystal growth in healthy Crystallization and tubular ectasia situation：
Visible control group renal tubule structure is normal under light microscopic, and has no obvious calcium oxalate crystal, lures visible kidney in stone group
Tubule is substantially expanded, the calcium oxalate crystal of visible water white transparency in most of renal tubules, and visible calcium oxalate is brilliant in the renal tubule of part
Body accumulates agglomerating, visible point-like calcium oxalate crystal in gamboge berry extract intervention group renal tubule, rare slabbing, calcium oxalate crystal
Deposition and tube chamber expand situation and substantially relatively lure stone group to improve.
Embodiment 4
The aqueous solution of gamboge berry extract, wherein, the content of gamboge berry extract is 0.1wt%.
Embodiment 5
The aqueous solution of gamboge berry extract, wherein, the content of gamboge berry extract is 1wt%.
Embodiment 6
The aqueous solution of gamboge berry extract, wherein, the content of gamboge berry extract is 2wt%.
Embodiment 7
The aqueous solution of gamboge berry extract, wherein, the content of gamboge berry extract is 5wt%.
Embodiment 8
The aqueous solution of gamboge berry extract, wherein, the content of gamboge berry extract is 10wt%.
Embodiment 9
A kind of beverage for suppressing lithangiuria and being formed and promoting dissolve stone：
Gamboge berry extract 2wt%
Stevioside 1wt%
Sorbic acid 0.1wt%
Water 96.9wt%
Embodiment 10
A kind of beverage for suppressing lithangiuria and being formed and promoting dissolve stone：
Gamboge berry extract 2wt%
White granulated sugar 1wt%
Sorbic acid 0.1wt%
Water 96.9wt%
The above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
Member, on the premise of the method for the present invention is not departed from, can also make some improvement and supplement, these are improved and supplement also should be regarded as
Protection scope of the present invention.
Claims (10)
1. application of the gamboge berry extract in the formation of suppression lithangiuria is prepared, promote the food or medicine of dissolve stone.
2. application according to claim 1, it is characterised in that the food is beverage.
3. application according to claim 1, it is characterised in that the lithangiuria is calcinm oxalate calculus, promotes dissolve stone
It is to promote calcinm oxalate calculus dissolving.
4. application according to claim 1, it is characterised in that the gamboge berry extract is water extract or alcohol extracting
Thing.
5. application according to claim 4, it is characterised in that the gamboge berry extract is made by the following method：
(1) dry gamboge shell is cut into pieces, the soak extraction in boiling water, extracting solution concentration is medicinal extract；
(2) ethanol is added into medicinal extract to be dissolved, filter out pectin, obtain concentrate.
6. application according to claim 4, it is characterised in that the gamboge berry extract is made by the following method：
(1) by gamboge pericarp ethanol soak extraction, it is gamboge pericarp quality to be extracted to soak the ethanol volume used every time
8 times, when immersion 48 is small every time, soak extraction 3 times, merges ethanol soaked extracting solution altogether, and the absolute ethyl alcohol that is concentrated under reduced pressure is soaked
Cream A；
(2) silica gel column chromatography separation is carried out to extractum A：Silica gel dosage is 18 times of medicinal extract, and specification is 200 mesh, and extractum A uses silicon
Plastic column chromatography is eluted with chloroform, elutes 8 column volumes, and the chloroform eluent that is concentrated under reduced pressure obtains medicinal extract B, medicinal extract
B obtains gamboge berry extract after drying.
7. a kind of suppression lithangiuria forms and promote the beverage of dissolve stone, include 0.1wt%~10wt%'s in the beverage
Gamboge berry extract.
8. beverage according to claim 7, it is characterised in that the content of gamboge berry extract is 2wt%.
9. beverage according to claim 7, it is characterised in that the beverage is made of following components：Garcinia Cambogia is extracted
Thing 2wt%, stevioside 1wt%, sorbic acid 0.1wt%, water 96.9wt%.
10. beverage according to claim 7, it is characterised in that the beverage is made of following components：Garcinia Cambogia is extracted
Thing 2wt%, white granulated sugar 1wt%, sorbic acid 0.1wt%, water 96.9wt%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711210091.1A CN107927498A (en) | 2017-11-28 | 2017-11-28 | A kind of beverage composition for treating dental erosion and its application for suppressing lithangiuria and forming and promote dissolve stone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711210091.1A CN107927498A (en) | 2017-11-28 | 2017-11-28 | A kind of beverage composition for treating dental erosion and its application for suppressing lithangiuria and forming and promote dissolve stone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107927498A true CN107927498A (en) | 2018-04-20 |
Family
ID=61949178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711210091.1A Pending CN107927498A (en) | 2017-11-28 | 2017-11-28 | A kind of beverage composition for treating dental erosion and its application for suppressing lithangiuria and forming and promote dissolve stone |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107927498A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108853170A (en) * | 2018-06-04 | 2018-11-23 | 南方医科大学南方医院 | The composition of oral dissolution calcinm oxalate calculus |
| CN110237113A (en) * | 2019-07-10 | 2019-09-17 | 华中农业大学 | A kind of plant extracts additive and the application of anti-Escherichia coli and coccidia mixed infection |
| CN110664964A (en) * | 2019-10-31 | 2020-01-10 | 武汉泰安康生物科技有限公司 | Medicine for preventing and treating urinary calculus and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1701675A (en) * | 2005-06-10 | 2005-11-30 | 张晶 | Fat-reducing candy |
| US20060040003A1 (en) * | 2004-08-10 | 2006-02-23 | Alvin Needleman | Dietary supplement for supressing appetite, enhancing and extending satiety, improving glycemic control, and stimulant free |
| CN103626644A (en) * | 2013-09-10 | 2014-03-12 | 上海中医药大学 | Preparation method of antitumor active components |
| CN104610049A (en) * | 2015-02-12 | 2015-05-13 | 白心亮 | Method for extracting hydroxyl citric acid from garcinia cambogia |
| US20150297545A1 (en) * | 2014-02-06 | 2015-10-22 | University Of Houston System | Organic acids as agents to dissolve calcium minerals in pathological calcification and uses thereof |
| KR101781365B1 (en) * | 2016-08-31 | 2017-09-25 | 주식회사 코씨드바이오팜 | Method for High Yield Extraction of Hydroxycitric Acid from Garcinia cambogia with Response Surface Methodology |
-
2017
- 2017-11-28 CN CN201711210091.1A patent/CN107927498A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060040003A1 (en) * | 2004-08-10 | 2006-02-23 | Alvin Needleman | Dietary supplement for supressing appetite, enhancing and extending satiety, improving glycemic control, and stimulant free |
| CN1701675A (en) * | 2005-06-10 | 2005-11-30 | 张晶 | Fat-reducing candy |
| CN103626644A (en) * | 2013-09-10 | 2014-03-12 | 上海中医药大学 | Preparation method of antitumor active components |
| US20150297545A1 (en) * | 2014-02-06 | 2015-10-22 | University Of Houston System | Organic acids as agents to dissolve calcium minerals in pathological calcification and uses thereof |
| CN104610049A (en) * | 2015-02-12 | 2015-05-13 | 白心亮 | Method for extracting hydroxyl citric acid from garcinia cambogia |
| KR101781365B1 (en) * | 2016-08-31 | 2017-09-25 | 주식회사 코씨드바이오팜 | Method for High Yield Extraction of Hydroxycitric Acid from Garcinia cambogia with Response Surface Methodology |
Non-Patent Citations (2)
| Title |
|---|
| JIHAE CHUNG,ET AL: "Molecular modifiers reveal a mechanism of pathological crystal growth inhibition", 《NATURE》 * |
| 孙学军: "科学家意外发现肾结石排石药", 《氢分子医学》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108853170A (en) * | 2018-06-04 | 2018-11-23 | 南方医科大学南方医院 | The composition of oral dissolution calcinm oxalate calculus |
| CN110237113A (en) * | 2019-07-10 | 2019-09-17 | 华中农业大学 | A kind of plant extracts additive and the application of anti-Escherichia coli and coccidia mixed infection |
| CN110237113B (en) * | 2019-07-10 | 2021-09-07 | 华中农业大学 | Plant extract additive for resisting mixed infection of escherichia coli and coccidian and application |
| CN110664964A (en) * | 2019-10-31 | 2020-01-10 | 武汉泰安康生物科技有限公司 | Medicine for preventing and treating urinary calculus and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107927498A (en) | A kind of beverage composition for treating dental erosion and its application for suppressing lithangiuria and forming and promote dissolve stone | |
| Akojie et al. | Antisickling activity of hydroxybenzoic acids in Cajanus cajan | |
| Sun et al. | Exploring the metabolic biomarkers and pathway changes in crucian under carbonate alkalinity exposure using high-throughput metabolomics analysis based on UPLC-ESI-QTOF-MS | |
| CN102994350A (en) | Preparation method of tartary buckwheat wine with function of reducing blood fat | |
| Jaturakan et al. | Combination of vitamin E and vitamin C alleviates renal function in hyperoxaluric rats via antioxidant activity | |
| CN104825516B (en) | Utilize the method for response phase method extraction Solidago Canadensis antioxidant content | |
| CN104840777B (en) | A kind of Chinese medicine preparation for treating diabetes and preparation method thereof | |
| CN108567955A (en) | A kind of pharmaceutical composition and preparation method thereof of prevention diabetic nephropathy | |
| CN106668058A (en) | Repair effect of traditional Chinese medicine component-radix morindae officinalis polysaccharide for injury to male reproductive system | |
| CN105238652B (en) | A kind of Penes wine and preparation method thereof | |
| CN103416347A (en) | Lifestyle hypertension animal model caused by drinking and high-sugar high-fat diet | |
| CN107281317A (en) | A kind of oral liquid for improving body immunity and preparation method thereof | |
| CN102068513A (en) | Application of coptis astragalus scutellaria composition in preparation of drug for preventing and treating diabetic complication | |
| CN103636839A (en) | Anti-fatigue tea | |
| CN103623150B (en) | Novel processing technology for lowering alisma nephrotoxicity | |
| Sarkiyayi et al. | Effect of ethanol leaf extract of Acacia nilotica on phenyl hydrazine induced anemia in rats | |
| CN103417476B (en) | Menbutone injection liquid for veterinary use and preparation method thereof | |
| CN104757681A (en) | Elsholtzia rugulosa drink and preparation technology thereof | |
| CN105030952B (en) | A kind of composition is preparing the application in preventing urinary calculus drug | |
| CN108888652A (en) | A kind of renal lobe beggarweed alcohol extract and its application | |
| CN112826835B (en) | Method for extracting active substances in honey | |
| Naeslund | Investigations into the transit of reducing substances from mother to foetus in alimentary hyperglycaemia | |
| CN108728320A (en) | A kind of production method of the barley wine with function of blood sugar reduction | |
| Shekokar | Phytochemical evaluation of ardra and shushka dosage forms and randomized controlled open labelled clinical trial of ecliptaalba hassk.(Bhringaraj) panchanga in iron deficiency anaemia. | |
| MASIBO | EFFICACY OF PREDNISOLONE IN THE MANAGEMENT OF ALCOHOL-INDUCED ADVERSE EFFECTS IN A RAT MODEL |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180420 |
|
| RJ01 | Rejection of invention patent application after publication |